{
    "clinical_study": {
        "@rank": "112823", 
        "arm_group": [
            {
                "arm_group_label": "MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in\n      subjects with moderate to severe psoriasis to assess the safety, tolerability,\n      immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple\n      subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F]\n      Nanobody)."
        }, 
        "brief_title": "Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic plaque psoriasis for at least 6 months before screening\n\n          -  Greater than or equal to (>=) 10% of BSA with plaques\n\n          -  Psoriasis Area and Severity Index (PASI) >=12\n\n          -  Static Physician's Global Assessment (sPGA) >=3 (where scores range from 0 [clear of\n             disease] to 5 [severe disease]) at the screening and baseline visits\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Any condition, including protocol-specified laboratory findings and findings in the\n             medical history or in the pre-trial assessments which in the Investigator's opinion\n             constitutes a risk or a contraindication for the subject's participation in the trial\n             or that could interfere with the trial objectives, conduct or evaluation\n\n          -  Currently having a form of non-plaque psoriasis as specified in the protocol\n\n          -  Drug induced psoriasis\n\n          -  Biological treatments as specified in the protocol, within 3 months prior to Day 1\n\n          -  Systemic immunosuppressants or phototherapy as specified in the protocol, within 1\n             month prior to Day 1\n\n          -  Topical corticosteroid treatments other than low-strength or lower-mid strength\n             corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day\n             1\n\n          -  Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or\n             IL-23 as specified in the protocol\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156466", 
            "org_study_id": "200574-003", 
            "secondary_id": "2013-005436-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "description": "MSB0010841 (Anti-IL-17A/F Nanobody) will be administered at a dose ranging from 30 milligram (mg) to 240 mg as subcutaneous injection every other week for a total duration of 6 weeks.", 
                "intervention_name": "MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "intervention_type": "Drug", 
                "other_name": "Anti-IL-17A/F Nanobody"
            }, 
            {
                "arm_group_label": "Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "description": "Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody) will be administered as subcutaneous injection every other week for a total duration of 6 weeks.", 
                "intervention_name": "Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Psoriasis", 
            "MSB0010841", 
            "Anti-IL17A/F Nanobody"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49 6151 72 5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: The Central Register of Clinical Trials", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Hungary: Scientific and Medical Research Council Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Czech Republic: Ethics Committee", 
                "Slovakia: State Institute for Drug Control", 
                "Slovak Republic: Ethics Committee"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Subjects With Treatment Emergent Adverse Events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 85"
            }, 
            {
                "description": "Number of subjects with local ISRs of swelling, redness, induration, bruising as assessed by the Investigator and severity of pain and itching as assessed by the subject will be reported.", 
                "measure": "Number of Subjects With Local Injection Site Reactions (ISRs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 43"
            }, 
            {
                "measure": "Percentage of Subjects with Anti-MSB0010841 Antibodies (BAbs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 85"
            }, 
            {
                "measure": "Levels of Pre-existing Anti-MSB0010841 Antibody", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "MSB0010841 (Anti-IL-17A/F Nanobody) Serum Concentration", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 15, 29, 43, 50, 63, 73, and 85"
            }, 
            {
                "measure": "Pharmacokinetics Profile post First and Third Dose of MSB0010841 (Anti-IL-17A/F Nanobody): AUC (0-t), AUC (0-tau), AUC (0-inf), Cpre, Cmin, Cmax, Cav, MRT (0-tau), MRT (0-inf), tmax, t1/2, lambda_z, CL/f, Vz/f, PTF, Accumulation Ratio of Cmax, and AUC", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 29, 43, 50, 63, 73, and 85"
            }, 
            {
                "measure": "Pharmacokinetics Profile Post Second Dose of MSB0010841 (Anti-IL-17A/F Nanobody): Cmax, tmax, Cpre", 
                "safety_issue": "No", 
                "time_frame": "Day 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156466"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Subjects With 50 or 75% Improvement in Psoriasis Area and Severity Index (PASI) Score Compared to Baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 85"
            }, 
            {
                "measure": "Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 43"
            }, 
            {
                "measure": "Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at least 2 Level Reduction From Baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 85"
            }, 
            {
                "measure": "Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Days 8, 15, 22, 29, 36, 43, 50, and 85", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Days 8, 15, 22, 29, 36, 43, 50, and 85"
            }, 
            {
                "description": "Psoriasis exacerbation is defined as either 1) A worsening of 25% over the baseline value of the PASI score (PASI score at any visit >=125% of baseline PASI) or 2) A reported adverse event (AE) suggesting disease worsening that is more inflammatory in nature compared to baseline and occurs either within pre-existing plaques, at previously uninvolved sites, or as new morphologies of disease compared to baseline.", 
                "measure": "Percentage of Subjects with Exacerbation of Psoriasis", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 85"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}